Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1149819 | 0.87 | ABCB1 (0.48) | SMN1; SMN2POLBKDM4EALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL4598508 | 0.81 | LMNA (0.46) | SMN1; SMN2POLBKDM4EALDH1A1TAAR1 | |
| Bromide SCHEMBL3607673 | 0.80 | L3MBTL1 (0.47) | AOC3ALDH1A1TAAR1CHRM2SLC6A4 | |
| Bromide SCHEMBL4178606 | 0.78 | POLB (0.39) | SMN1; SMN2POLBKDM4EALDH1A1MAPT | |
| Bromide SCHEMBL26919058 | 0.77 | PKM (0.43) | SMN1; SMN2POLBKDM4EALDH1A1PKM | |
| Bromide SCHEMBL7804211 | 0.76 | HTR2A (0.54) | KDM4EAOC3TAAR1CYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL5829422 | 0.76 | L3MBTL1 (0.47) | AOC3ALDH1A1TAAR1CHRM2SLC6A4 | |
| Bromide SCHEMBL723263 | 0.75 | PTGS2 (0.47) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT | |
| Bromide SCHEMBL17337941 | 0.75 | SLC6A2 (0.42) | SMN1; SMN2KDM4EALDH1A1SLC6A4TRAP1 | |
| Bromide SCHEMBL4178373 | 0.74 | TRAP1 (0.43) | KDM4EALDH1A1SLC6A4TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620466-A1 | TRIMETHOXYSTYRYL DERIVATIVES FOR USE IN THE TREATMENT OF PACLITAXEL-RESISTANT CANCER | Instituto de Investigación Biomédica de Salamanca De la Fundación Instituto Ciencia de la Salud De Castilla y León (ES) | 2025-09-24 | — | — | EP | disclosed |
| US-6972299-B2 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | HOFFMANN-LA ROCHE INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-6927232-B2 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | HOFFMAN-LA ROCHE INC. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1349839-B8 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20050131043-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1349839-B1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6706707-B2 | TREATMENT OR PREVENTION OF MGLUR5 RECEPTOR MEDIATED DISORDERS. | HOFFMAN-LA ROCHE INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030225070-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030208082-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2003-11-06 | — | — | US | disclosed |
| EP-1349839-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | F.HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | US | disclosed |
| WO-2002046166-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131043-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM6 | CHRM2 108/4885SMN1; SMN2 2192/4885POLB 4639/4885 |
| US-20030208082-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM1 | CHRM2 827/4885SMN1; SMN2 2523/4885POLB 4514/4885 |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM1 | CHRM2 827/4885SMN1; SMN2 2523/4885POLB 4514/4885 |
| US-20030225070-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, HRH4 | CHRM2 963/4885SMN1; SMN2 2911/4885POLB 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.